ValiRx PLC - Approval of protocol amendment for VAL201
VAL Thu, 20 Jun 2019, 12:20pm BST
ValiRx accelerates the development of treatments in cancer and women’s health to improve patient lives. We provide the scientific, financial and commercial framework to enable the rapid translation of innovative science into clinical development.
Industry: Health Care
Contact: +44 (0)2476 796496
George Morris, COO, discusses the significant amendment to the VAL201 protocol and next steps for the clinical trial.